Pharmacogenetic association of diabetes-associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors —results of the Heinz Nixdorf Recall Study

HMG-CoA-Reductase inhibitors (HMGRIs) are currently the most widely used group of drugs in patients with coronary artery disease (CAD) and are given preemptively to patients with high levels of cholesterol, including those with diabetes mellitus (DM). However, intake of HMGRIs also increases the pro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Naunyn Schmiedebergs Arch Pharmacol
Päätekijät: Pechlivanis, Sonali, Jung, Dominik, Moebus, Susanne, Lehmann, Nils, Mahabadi, Amir A., Hoffmann, Per, Erbel, Raimund, Nöthen, Markus M., Bachmann, Hagen S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2021
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8298241/
https://ncbi.nlm.nih.gov/pubmed/34021798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00210-021-02100-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia